Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study
TACE combined with TKIs has good efficacy and safety in the treatment of HCC recurrence post-LT and is expected to prolong survival.
Authors
- Dan Zhu (ORCID: https://orcid.org/0000-0003-0485-9456)
- Haiyan Shi (ORCID: https://orcid.org/0000-0003-1041-6483)
- Zheng Ye (ORCID: https://orcid.org/0000-0003-1912-6992)
- Shao Zhong (ORCID: https://orcid.org/0000-0002-9054-6554)
- Ye Sang (ORCID: https://orcid.org/0009-0009-8002-7070)
- Jianfeng Zhang (ORCID: https://orcid.org/0000-0002-3270-0533)
- Zhuang Li (ORCID: https://orcid.org/0000-0001-6855-2803)
- Jingfeng Zhang (ORCID: https://orcid.org/0000-0003-4788-0634)
- Guohong Cao
- Meng-chen Song
- Al-Kalei Ama
Institutions
- Ningbo No. 2 Hospital (CN)
- Zhejiang Hospital (CN)
- Zhejiang Shuren University (CN)
- Ningbo No.6 Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12885-025-14446-9
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32